KYKOF (Kyowa Kirin Co) EBIT: $651 Mil (TTM As of Dec. 2025)


KYKOF Kyowa Kirin Co Ltd KYKOF
82 GF Score
Price $14.43
GF Value $17.92
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Kyowa Kirin Co EBIT?

Kyowa Kirin Co KYKOF 82 EBIT is $651 Mil as of Dec. 2025. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.92 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Kyowa Kirin Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $255 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $651 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kyowa Kirin Co's annualized ROC % for the quarter that ended in Dec. 2025 was 19.40%. Kyowa Kirin Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 72.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Kyowa Kirin Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 9.67%.


Kyowa Kirin Co  (OTCPK:KYKOF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kyowa Kirin Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=1058.732 * ( 1 - 12.36% )/( (4734.284 + 4831.658)/ 2 )
=927.8727248/4782.971
=19.40 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7286.797 - 914.638 - ( 1637.875 - max(0, 1252.241 - 3319.271+1637.875))
=4734.284

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7105.538 - 863.99 - ( 1409.89 - max(0, 1161.389 - 3164.211+1409.89))
=4831.658

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Kyowa Kirin Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1019.324/( ( (884.596 + max(429.155, 0)) + (905.782 + max(592.932, 0)) )/ 2 )
=1019.324/( ( 1313.751 + 1498.714 )/ 2 )
=1019.324/1406.2325
=72.49 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1026.809 + 482.048 + 172.539) - (914.638 + 0 + 337.603)
=429.155

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1162.204 + 432.543 + 159.574) - (863.99 + 0 + 297.399)
=592.932

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Kyowa Kirin Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=651.228/6733.556
=9.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyowa Kirin Co EBIT Related Terms


Kyowa Kirin Co EBIT Historical Data

* Premium members only.

The historical data trend for Kyowa Kirin Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyowa Kirin Co EBIT Chart

Kyowa Kirin Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 537.34 508.91 676.73 591.56 582.79

Kyowa Kirin Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.68 115.28 179.06 254.83 102.06

KYKOF vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyowa Kirin Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kyowa Kirin Co's EV-to-EBIT falls into.


KYKOF
82GF Score
Kyowa Kirin Co Ltd KYKOF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyowa Kirin Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $651 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $651 Mil mean?
Kyowa Kirin Co (KYKOF) has a EBIT of $651 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kyowa Kirin Co.
Is Kyowa Kirin Co's EBIT too high?
Kyowa Kirin Co's current EBIT is $651 Mil. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's EBIT compare to ZTS?
Kyowa Kirin Co's EBIT of $651 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Kyowa Kirin Co. Kyowa Kirin Co's current EBIT is $651 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.92, compared to a current price of $14.43 — trading 19.5% below its estimated fair value. The current EBIT is $651 Mil. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current EBIT is $651 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?

Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued. The current stock price of $14.43 is trading 19.5% below its estimated GF Value™ of $17.92. GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.

Key valuation signals for KYKOF:

  • EBIT: $651 Mil
  • GF Value™: $17.92 vs. price of $14.43 (19.5% below fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyowa Kirin Co Business Description

Address 1-9-2 Otemachi, Chiyoda-ku, Chiyoda-ku, Tokyo, JPN, 100-0004
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score

Get the complete analysis for KYKOF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.43
Price
$17.92
GF Value